Gitelman syndrome is an autosomal recessive salt-losing tubulopathy first described in 1966. It arises from inactivating mutations in SLC12A3, the gene encoding the thiazide-sensitive sodium-chloride cotransporter known as NCC. This transporter sits exclusively on the apical membrane of epithelial cells lining the distal convoluted tubule, a short but critical segment of the nephron where sodium and chloride are reclaimed from the forming urine. When NCC fails, the kidney cannot properly conserve sodium, potassium, chloride, and magnesium. The biochemical signature is distinctive: hypokalemic metabolic alkalosis, low serum magnesium, unusually low urinary calcium, and appropriately elevated renin in a patient with normal or low blood pressure. With an estimated prevalence of roughly 1 to 10 per 40,000 people, it is among the more common inherited renal tubulopathies, yet its symptoms—muscle weakness, cramps, fatigue, salt craving, thirst—are so nonspecific that diagnosis is often delayed into adolescence or adulthood.

The patient’s history illustrates that delay vividly. As a child she suffered leg numbness while walking, night cramps, and bedwetting until about age twelve. She had fainted at least twice during emotional stress as a teenager, and her sister took potassium supplements for chronic hypokalemia. Her parents were first cousins, a clue pointing to a recessive condition. Despite these signals and decades of documented low potassium, no unifying diagnosis emerged until syncope began clustering dangerously. On admission her blood pressure was 97/62 mmHg with a heart rate of 60 beats per minute. Laboratory testing confirmed the classic tetrad: hypokalemic metabolic alkalosis with hypomagnesemia, hypocalciuria, and secondary hyperreninism. An electrocardiogram revealed sinus bradycardia, a prolonged QRS interval of 154 milliseconds with right bundle branch and left anterior fascicular blocks, and a QTc of 465 milliseconds with U waves—conduction abnormalities consistent with the electrical instability that potassium and magnesium depletion can produce.

The arrhythmia workup was thorough but largely unrevealing. Two weeks of continuous cardiac event telemetry during three fainting spells captured only sinus rhythm with occasional premature atrial and ventricular contractions—no sustained arrhythmias. Echocardiography, myocardial perfusion imaging, kidney and bladder ultrasound, electroencephalography, and advanced imaging of the head and neck were all normal. Tilt-table testing, however, showed distal sudomotor deficits and borderline heart rate and blood pressure responses during upright tilt, hinting at early autonomic neuropathy. The decisive clue came from the urine: ongoing potassium wasting paired with hypocalciuria. That combination prompted genetic testing, which identified a homozygous missense mutation in SLC12A3—c.2221G>A, p.Gly741Arg—confirming Gitelman syndrome. Notably, this variant was among the original mutations discovered when the genetic basis of the disease was first established in the 1990s, and it remains one of the most common pathogenic missense changes reported across cohorts, with a carrier allele frequency of about 0.04 percent in the gnomAD database.

Why does losing sodium upstream cause potassium wasting downstream? The pathophysiology is a cascade. Reduced NCC activity in the distal convoluted tubule means more sodium chloride reaches the collecting duct. There, the extra sodium drives electrogenic reabsorption through epithelial sodium channels, which depolarizes the tubular cells and creates a stronger electrical gradient favoring potassium secretion through ROMK and Maxi-K channels. The high tubular flow rate adds a mechanical stimulus, promoting flow-induced potassium secretion via BK channels and stimulating synthesis of prostaglandin E2, which further encourages potassium loss. Finally, the mild volume depletion characteristic of the disease activates the renin-angiotensin-aldosterone axis, and aldosterone amplifies distal potassium secretion even more. Interestingly, the authors note that potassium depletion itself can blunt aldosterone secretion independent of volume status, which may mask the expected hyperaldosteronism and complicate interpretation.

Treatment proved refractory at first. Even with a staggering total daily dose of 240 milliequivalents of potassium chloride plus magnesium oxide, sodium chloride, and the potassium-sparing diuretic amiloride, her serum potassium and magnesium remained stubbornly low. To help her return safely to work, clinicians escalated amiloride to 10 milligrams and added midodrine, a pressor agent, along with the nonsteroidal anti-inflammatory naproxen to raise blood pressure and reduce renal electrolyte excretion. The crucial innovation was monitoring: monthly spot urine and serum potassium measurements guided stepwise titration of amiloride up to 20 milligrams daily until urinary potassium wasting was suppressed, serum potassium improved, and the fainting stopped. When a major life event led her to stop all medications except potassium chloride about three months later, kaliuresis, hypokalemia, and syncope all returned—a natural experiment demonstrating that the multimodal regimen, not the supplements alone, was doing the heavy lifting.

The case is also a masterclass in interpreting spot urine electrolytes, which have no established universal reference ranges and must be read against the expected renal response for a given clinical context. Under dietary potassium restriction, urinary potassium excretion normally falls to 10 to 15 milliequivalents per day; excretion above 30 to 40 milliequivalents per day during hypokalemia is unmistakable evidence of renal wasting. A further wrinkle is urine concentration itself—dilute urine lowers measured potassium, concentrated urine raises it. Fortunately, this patient’s urine osmolality was remarkably consistent across visits, allowing straightforward comparison of serial values. The authors also flag a subtle complication: chronic hypokalemia can induce partial vasopressin resistance, an acquired urine-concentrating defect. Children with Gitelman syndrome have been shown to produce notably dilute urine after overnight water deprivation compared with unaffected peers, and while they concentrate better than patients with Bartter syndrome, these subtle water-handling impairments may be underrecognized and may exacerbate volume depletion.

Therapeutic options in Gitelman syndrome rest on limited evidence because the disease is rare. Standard care involves lifelong oral supplementation with sodium, potassium, chloride, and magnesium salts, with potassium-sparing diuretics, NSAIDs, and renin-angiotensin-aldosterone antagonists reserved for selected cases. NSAIDs curb renin secretion during hypovolemia; mineralocorticoid receptor antagonists and ENaC inhibitors counteract aldosterone-driven and flow-driven potassium secretion in the aldosterone-sensitive distal nephron. A randomized crossover study of 30 patients taking potassium and magnesium supplements found that indomethacin 75 milligrams, eplerenone 150 milligrams, and amiloride 20 milligrams each raised plasma potassium, with indomethacin most effective but most burdensome to the gut and kidneys. Diuretics also shrink extracellular fluid volume and can worsen orthostatic hypotension, although one small study found no obvious clinical impact. In this patient, sodium and naproxen titration was limited by palatability and dyspepsia, illustrating how real-world tolerability constrains theoretical regimens.

The authors argue that serial spot urine potassium measurements added something serum potassium alone could not. Hypokalemia in Gitelman syndrome is often treatment-resistant, and quantifying urinary losses tells the clinician how much oral repletion is needed to achieve a net positive balance. Spot samples are also far easier to obtain than 24-hour collections. When a potassium-sparing diuretic is working, urine potassium falls—and once kaliuresis is suppressed, pushing the diuretic higher adds little, whereas more potassium chloride becomes the rational lever. Suppressed kaliuresis also served as an objective marker of adherence. KCl alone, by contrast, would never have reduced urinary potassium excretion. The team acknowledges gaps: the field still lacks validated urine values and creatinine ratios that formally define potassium, sodium, and chloride wasting, and there was insufficient time on the effective regimen to test whether normal serum potassium could have been achieved with higher potassium chloride dosing.

The broader lesson reaches beyond this single patient. Syncope in Gitelman syndrome is mechanistically plausible but rarely documented; palpitations and arrhythmias occur in up to 60 percent of patients, and ventricular tachycardia or sudden cardiac death, while rare, remain feared complications. Whether this patient’s fainting stemmed from hypokalemia-induced conduction delays, volume depletion, impaired vasoconstriction, or early autonomic dysfunction cannot be fully disentangled, but severe hypokalemia with ongoing renal wasting justified aggressive correction regardless. The authors call for urine electrolytes to be integrated into routine practice for patients with blood pressure or electrolyte disorders, and for genetic testing of renal electrolyte transporter genes in patients with recurrent syncope and chronic electrolyte abnormalities. In an era of ever more sophisticated diagnostics, a simple spot urine sample, interpreted with physiological rigor, proved the thread that unraveled a decades-old mystery and, ultimately, kept a patient on her feet.

Subject of Research: Gitelman syndrome diagnosis and electrolyte-guided treatment of recurrent syncope

Article Title: Urine electrolytes guide treatment of Gitelman syndrome and recurrent syncope—A case report

Article References: Urine electrolytes guide treatment of Gitelman syndrome and recurrent syncope—A case report. (n.d.). https://doi.org/10.14814/phy2.71043

Image Credits: AI Generated

DOI: 10.14814/phy2.71043

Keywords: Gitelman syndrome, SLC12A3, hypokalemia, syncope, urine electrolytes, distal convoluted tubule, amiloride, renal tubulopathy, electrolyte disorders, cardiac arrhythmia, NCC cotransporter, case report

Enter RGS2, or regulator of G-protein signaling 2, a protein that has fascinated cardiovascular physiologists for more than two decades. RGS2 acts as a negative regulator of Gq-coupled receptors, and chief among its targets is the angiotensin II type 1 receptor, or AT1R, the receptor through which angiotensin II executes many of its pressor and remodeling effects. Mice engineered to lack RGS2 throughout the body develop severe hypertension and prolonged vasoconstrictor signaling, and reduced RGS2 expression has been documented in hypertensive patients, where it correlates with exaggerated calcium mobilization and ERK1/2 phosphorylation in response to angiotensin II. RGS2 is also abundantly expressed in myeloid cells, which raises an intriguing paradox: if immune cells promote hypertension and RGS2 restrains angiotensin II signaling, should removing RGS2 specifically from myeloid cells unleash worsened hypertensive disease?

A team led by Nakagawa and colleagues set out to answer precisely that question. Using an elegant conditional knockout strategy, they generated mice in which RGS2 was selectively ablated in myeloid cells, a model designated RGS2 LysM-KO, and then challenged these animals with chronic angiotensin II infusion. The expectation, shared by the investigators themselves and by much of the field, was that loss of the AT1R brake in macrophages and related cells would amplify inflammatory signaling and thereby exacerbate hypertension and cardiovascular-renal injury.

The results defied those expectations. Across every measure the researchers examined, the myeloid-specific RGS2 knockout mice behaved essentially like their normal counterparts. Blood pressure responses to chronic angiotensin II were indistinguishable between the groups. Cardiac and renal damage, typically hallmarks of sustained pressor challenge, did not differ. Vascular dysfunction was unchanged, and inflammatory profiles failed to reveal any meaningful divergence attributable to the loss of myeloid RGS2. The authors concluded that myeloid RGS2 is not involved in angiotensin II-induced hypertension or cardiovascular-renal organ damage, a finding with significant conceptual implications.

Perhaps the most important implication is what the study says about the devastating hypertension of whole-body RGS2 deficiency. If deleting the protein in immune cells accomplishes nothing, then the severe, damaging hypertension seen when RGS2 is absent everywhere must be driven exclusively by altered RGS2 signaling in vascular and renal epithelial tissues rather than by the immune system. The brake that matters, in other words, is the one applied within the blood vessel wall and the kidney tubule, not the one applied inside infiltrating macrophages. This reallocation of responsibility helps sharpen where therapeutic efforts to modulate RGS2 signaling should be aimed.

Writing in a linked commentary in the same journal, Lorenzo A. Calò, Martina Cacciapuoti, and Paul A. Davis place these murine findings in a striking human context. Their laboratory has long studied Gitelman’s and Bartter’s syndromes, rare genetic tubulopathies caused by defects in specific kidney transporters and ion channels. These disorders are, in a sense, the mirror image of hypertension: they represent human models of endogenous angiotensin II signaling antagonism. Patients with Gitelman’s or Bartter’s syndrome display marked activation of the renin-angiotensin-aldosterone system, with high circulating levels of both angiotensin II and aldosterone, yet despite this hormonal surge they present with hypotension or normotension rather than hypertension.

The clinical paradox deepens on closer inspection. Beyond their low blood pressure, patients with these syndromes show hyporesponsiveness to pressor agents and display activation of antiatherosclerotic and antiremodeling defenses. Their vascular biology features reduced Rho kinase signaling, increased nitric oxide bioavailability, and diminished oxidative stress and oxidative stress-related signaling, all in the face of elevated angiotensin II. Something powerful is damping down the signaling that angiotensin II normally delivers through the AT1 receptor, and the commentary authors argue that RGS2 is a central player in this endogenous antagonism.

The cellular evidence they have accumulated is compelling. In fibroblasts derived from patients with Gitelman’s and Bartter’s syndromes, both RGS2 RNA and protein abundance are increased compared with cells from healthy normotensive subjects. Functionally, this elevated RGS2 blunts angiotensin II signaling at multiple levels: it attenuates short-term signaling, including intracellular calcium release and the calcium-protein kinase C pathway in vascular smooth muscle cells, and it also dampens long-term proliferative and profibrotic responses that drive remodeling. Most tellingly, when the researchers silenced RGS2 in fibroblasts from these patients, the cells reverted to a hypertensive-like angiotensin II response, characterized by increased intracellular calcium release and ERK1/2 phosphorylation. In other words, removing the RGS2 brake in human cells restores the very signaling signature that defines hypertensive disease.

Taken together, the mouse knockout study and the human syndrome data demonstrate that RGS2 regulation of angiotensin II signaling through the Gq/AT1R axis, and its downstream consequences for hypertension and cardiovascular-renal remodeling, differ substantially depending on the level and the location of the RGS2 system being probed. A brake present in immune cells appears dispensable for pressor responses in mice, whereas abundant RGS2 in vascular cells of patients with inherited angiotensin signaling antagonism exerts profound hypotensive and antiremodeling effects. Context, cellular identity, and tissue distribution are everything. The findings caution against assuming that a regulatory protein implicated in immune-driven inflammation will necessarily shape blood pressure outcomes when manipulated within the immune compartment.

The commentary authors look forward to future work from the Nakagawa group addressing the major limitations acknowledged in the study, including the angiotensin II doses and time points employed and the need for more selective targeting methods for myeloid-specific ablation. Such refinements could reveal subtler roles for myeloid RGS2 that the current model missed, or they could further cement the conclusion that the vascular and renal epithelium are where RGS2 truly determines the course of hypertensive disease. Either way, the convergence of a clean genetic experiment in mice with mechanistic insights from rare human syndromes offers a unusually clear picture of how one small regulatory protein helps set the tone of the renin-angiotensin system, and why understanding where a molecule acts matters as much as knowing what it does.

Subject of Research: The role of RGS2 regulation of angiotensin II signaling in hypertension and cardiovascular-renal remodeling

Article Title: Although myeloid‐cell RGS2 knockout does not affect Ang II–induced hypertension/organ damage in mice, high RGS2 in Gitelman/Bartter syndromes—human models of endogenous Ang II signaling antagonism—is associated with hypotensive/antiremodeling effects

Article References: Calò, L. A., Cacciapuoti, M., & Davis, P. A. (2026). Although myeloid‐cell RGS2 knockout does not affect Ang II –induced hypertension/organ damage in mice, high RGS2 in Gitelman/Bartter syndromes—human models of endogenous Ang II signaling antagonism—is associated with hypotensive/antiremodeling effects. Physiological Reports, 14(18), Article e71110. https://doi.org/10.14814/phy2.71110

Image Credits: AI Generated

DOI: 10.14814/phy2.71110

Keywords: RGS2, angiotensin II, hypertension, myeloid cells, Gitelman syndrome, Bartter syndrome, AT1 receptor, blood pressure, vascular remodeling, G-protein signaling, Although, myeloid